In fact, key metabolic features of T2D, such as hyperinsulinemia, chronic low‐grade inflammation, and impaired glucose homeostasis, may modulate the functional effects of CDKN1B and TCF7L2 variants. The gene discussed is CDKN1B; the disease is Hyperinsulinemia.